Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells.
glioblastoma
immune evasion
immunotherapy
peptide and mRNA vaccines
tumor microenvironment
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
04
2021
accepted:
29
07
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
7
9
2021
Statut:
epublish
Résumé
According to the invasive nature of glioblastoma, which is the most common form of malignant brain tumor, the standard care by surgery, chemo- and radiotherapy is particularly challenging. The presence of glioblastoma stem cells (GSCs) and the surrounding tumor microenvironment protects glioblastoma from recognition by the immune system. Conventional therapy concepts have failed to completely remove glioblastoma cells, which is one major drawback in clinical management of the disease. The use of small molecule inhibitors, immunomodulators, immunotherapy, including peptide and mRNA vaccines, and virotherapy came into focus for the treatment of glioblastoma. Although novel strategies underline the benefit for anti-tumor effectiveness, serious challenges need to be overcome to successfully manage tumorigenesis, indicating the significance of developing new strategies. Therefore, we provide insights into the application of different medications in combination to boost the host immune system to interfere with immune evasion of glioblastoma cells which are promising prerequisites for therapeutic approaches to treat glioblastoma patients.
Identifiants
pubmed: 34485282
doi: 10.3389/fcell.2021.695325
pmc: PMC8415230
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
695325Informations de copyright
Copyright © 2021 Burster, Traut, Yermekkyzy, Mayer, Westhoff, Bischof and Knippschild.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Cancer Res. 2019 Oct 1;25(19):5799-5807
pubmed: 31320597
BMC Cancer. 2020 Mar 12;20(1):213
pubmed: 32164609
Neuro Oncol. 2020 May 05;:
pubmed: 32369601
Cell Stem Cell. 2020 Jan 2;26(1):48-63.e6
pubmed: 31901251
Cell Oncol (Dordr). 2019 Jun;42(3):287-301
pubmed: 30859392
Wien Med Wochenschr. 2011 Jan;161(1-2):13-9
pubmed: 21312094
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Ir J Med Sci. 2021 Aug;190(3):905-911
pubmed: 33155104
Drug Deliv Transl Res. 2021 May 30;:
pubmed: 34053034
Adv Radiat Oncol. 2020 May 27;5(4):743-745
pubmed: 32775785
ScientificWorldJournal. 2012;2012:838916
pubmed: 22431925
J Clin Invest. 2015 Sep;125(9):3356-64
pubmed: 26168215
PLoS One. 2014 Apr 10;9(4):e94050
pubmed: 24722669
Clin Cancer Res. 2017 Jan 1;23(1):124-136
pubmed: 27358487
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Sci Rep. 2021 Jan 11;11(1):413
pubmed: 33432067
Neuro Oncol. 2010 Nov;12(11):1113-25
pubmed: 20667896
Oncotarget. 2018 Apr 24;9(31):22194-22219
pubmed: 29774132
Nat Rev Clin Oncol. 2018 Jul;15(7):422-442
pubmed: 29643471
Nat Immunol. 2019 Sep;20(9):1100-1109
pubmed: 31358997
Arch Pharm Res. 2019 Mar;42(3):224-231
pubmed: 30680545
PLoS One. 2013 Sep 13;8(9):e74548
pubmed: 24058588
J Mol Med (Berl). 2020 Jan;98(1):1-10
pubmed: 31650201
Clin Cancer Res. 2020 Oct 15;26(20):5297-5303
pubmed: 32719000
Oncotarget. 2016 Jan 26;7(4):4369-78
pubmed: 26716896
Neuro Oncol. 2014 Dec;16(12):1575-84
pubmed: 25082799
J Clin Oncol. 2011 Sep 20;29(27):3611-9
pubmed: 21844505
Nat Rev Drug Discov. 2009 Jan;8(1):23-33
pubmed: 19079127
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Neurol India. 2002 Sep;50(3):290-4
pubmed: 12391455
Pharmaceuticals (Basel). 2021 Mar 08;14(3):
pubmed: 33800301
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cells. 2020 Jan 21;9(2):
pubmed: 31973059
Oncogene. 2008 Nov 6;27(52):6646-56
pubmed: 18663354
Biotechnol Adv. 2020 May - Jun;40:107534
pubmed: 32088327
Int J Biochem Cell Biol. 2005 Feb;37(2):267-71
pubmed: 15474972
Clin Microbiol Rev. 2009 Apr;22(2):240-73, Table of Contents
pubmed: 19366914
Nat Commun. 2020 Mar 20;11(1):1508
pubmed: 32198351
Nature. 2019 Jan;565(7738):234-239
pubmed: 30568305
Onco Targets Ther. 2018 Oct 23;11:7301-7314
pubmed: 30425521
Chin Neurosurg J. 2020 Sep 3;6:31
pubmed: 32922959
Lancet Oncol. 2010 Dec;11(12):1149-59
pubmed: 21094089
Clin Cancer Res. 2016 Oct 1;22(19):4776-4785
pubmed: 27225692
J Neurol Sci. 2020 May 15;412:116824
pubmed: 32299010
Nat Rev Cancer. 2005 Apr;5(4):275-84
pubmed: 15803154
J Exp Clin Cancer Res. 2016 Mar 25;35:55
pubmed: 27015814
Drugs. 2007;67(15):2277-88; discussion 2289-90
pubmed: 17927288
J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):763-8
pubmed: 10567494
Cell Death Dis. 2018 Nov 1;9(11):1112
pubmed: 30385739
Neuro Oncol. 2015 Jun;17(6):854-61
pubmed: 25586468
Cancers (Basel). 2020 Mar 22;12(3):
pubmed: 32235752
Neoplasia. 2009 Aug;11(8):743-52
pubmed: 19649204
Oncology (Williston Park). 2015 Apr;29(4):282-94
pubmed: 25952492
Acta Neuropathol. 2013 Apr;125(4):609-20
pubmed: 23344256
Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217
pubmed: 29075855
J Neurochem. 2004 Dec;91(6):1275-83
pubmed: 15584904
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33433624
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Clin Cancer Res. 2015 Aug 1;21(15):3384-92
pubmed: 26240290
Oncogene. 2001 Sep 13;20(41):5789-98
pubmed: 11593384
J Neurooncol. 2015 Jul;123(3):441-8
pubmed: 26093618
Neurotherapeutics. 2017 Apr;14(2):358-371
pubmed: 28299724
Neuro Oncol. 2016 Aug;18(8):1137-45
pubmed: 26843484
J Neurooncol. 2021 Jan;151(1):41-53
pubmed: 32253714
Drug Resist Updat. 2019 Jan;42:35-45
pubmed: 30877905
Neurology. 2020 Oct 6;95(14):e2016-e2027
pubmed: 32546654
Trends Immunol. 2012 Dec;33(12):579-89
pubmed: 22926201
J Biol Chem. 2004 Apr 30;279(18):19133-40
pubmed: 14966123
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4120-5
pubmed: 12646700
Cell Death Dis. 2020 Jun 25;11(6):485
pubmed: 32587256
Neuro Oncol. 2019 Jul 11;21(7):923-933
pubmed: 30753611
Neuro Oncol. 2018 Nov 12;20(12):1566-1572
pubmed: 29733389
Clin Cancer Res. 2013 Jan 1;19(1):205-14
pubmed: 22872572
Oncology (Williston Park). 2015 Oct;29(10):720-7
pubmed: 26470893
Br J Cancer. 2007 May 21;96(10):1560-8
pubmed: 17453002
J Transl Med. 2018 May 29;16(1):142
pubmed: 29843811
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Nat Commun. 2017 Oct 20;8(1):1067
pubmed: 29057925
Nat Rev Neurol. 2016 Apr;12(4):190
pubmed: 27020557
Hum Vaccin Immunother. 2014;10(11):3139-45
pubmed: 25483653
Nat Neurosci. 2021 Feb;24(2):168-175
pubmed: 33257876
Front Surg. 2016 Mar 02;3:11
pubmed: 26973839
Biochim Biophys Acta Mol Cell Res. 2017 Mar;1864(3):594-603
pubmed: 28040478
Sci Transl Med. 2016 Dec 21;8(370):370ra180
pubmed: 28003545
CNS Drugs. 2020 Feb;34(2):127-145
pubmed: 31916100
Methods Mol Biol. 2016;1403:797-817
pubmed: 27076168
Neuro Oncol. 2011 Nov;13(11):1213-24
pubmed: 21757445
Neuro Oncol. 2014 Jan;16(2):274-9
pubmed: 24335700
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Acta Neuropathol. 2004 Mar;107(3):272-6
pubmed: 14730455
Cancer Res. 2007 Oct 15;67(20):9630-6
pubmed: 17942891
Cancer Immunol Immunother. 2013 Jan;62(1):125-35
pubmed: 22847020
Cancers (Basel). 2019 Nov 16;11(11):
pubmed: 31744072
Brain Res. 2021 May 1;1758:147344
pubmed: 33556379
Biosci Rep. 2015 Jun 12;35(4):
pubmed: 26182432
Biomedicines. 2019 Sep 09;7(3):
pubmed: 31505812
JCI Insight. 2016;1(2):
pubmed: 26973881
Front Pharmacol. 2017 May 09;8:242
pubmed: 28536525
Front Oncol. 2020 Jan 17;9:1547
pubmed: 32010632
Front Oncol. 2020 Nov 16;10:566599
pubmed: 33312949
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Expert Opin Investig Drugs. 2008 Nov;17(11):1749-60
pubmed: 18922110
Int J Mol Med. 2015 Dec;36(6):1677-84
pubmed: 26459752
Cancer. 2017 Mar 1;123(5):734-750
pubmed: 27875627
EMBO Mol Med. 2019 Oct;11(10):e10769
pubmed: 31468706
JAMA Oncol. 2021 May 1;7(5):675-676
pubmed: 33475680
Front Immunol. 2018 Dec 03;9:2804
pubmed: 30559743
Mol Cell Biochem. 2011 May;351(1-2):41-58
pubmed: 21210296
Anticancer Agents Med Chem. 2016;16(1):101-7
pubmed: 26299661
Curr Pharmacol Rep. 2016 Feb;2(1):1-10
pubmed: 27088072
Int J Mol Sci. 2020 Jul 25;21(15):
pubmed: 32722427
Lab Invest. 2017 May;97(5):498-518
pubmed: 28287634
Cancer Biol Ther. 2019;20(8):1083-1090
pubmed: 31068075
Semin Oncol. 2003 Apr;30(2):300-4
pubmed: 12720157
AJNR Am J Neuroradiol. 2000 May;21(5):891-9
pubmed: 10815665
Nat Commun. 2018 Dec 17;9(1):5341
pubmed: 30559424
Neuro Oncol. 2001 Apr;3(2):82-8
pubmed: 11296484
Curr Neurol Neurosci Rep. 2016 Feb;16(2):13
pubmed: 26750128
PLoS One. 2013 Apr 23;8(4):e61895
pubmed: 23626745
Cancer Res. 2016 May 1;76(9):2552-60
pubmed: 27013192
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
J Neurooncol. 2012 Dec;110(3):359-68
pubmed: 23096132
J Cereb Blood Flow Metab. 2001 Jan;21(1):61-8
pubmed: 11149669
J Immunol. 2002 May 1;168(9):4772-80
pubmed: 11971028
Biomedicines. 2020 Apr 20;8(4):
pubmed: 32326020
Mol Neurobiol. 2020 May;57(5):2461-2478
pubmed: 32152825
JCI Insight. 2016 Jul 7;1(10):
pubmed: 27453950
Cancer Immunol Immunother. 2013 Sep;62(9):1499-509
pubmed: 23817721
Cancer Treat Rev. 2019 Nov;80:101896
pubmed: 31541850
Neuro Oncol. 2017 Aug 1;19(8):1047-1057
pubmed: 28371827
J Neurooncol. 2004 Nov;70(2):247-256
pubmed: 15674482
Sci Signal. 2016 Feb 16;9(415):ra19
pubmed: 26884601
Cancers (Basel). 2020 Aug 01;12(8):
pubmed: 32752193
Neurotherapeutics. 2017 Apr;14(2):333-344
pubmed: 28265902
Cells. 2021 Jan 29;10(2):
pubmed: 33572835
Biomedicines. 2019 Nov 27;7(4):
pubmed: 31783653
Cancer Res. 2009 Mar 15;69(6):2358-64
pubmed: 19258515
Surg Neurol. 2000 Apr;53(4):360-8; discussion 368-9
pubmed: 10825522
Mol Ther Oncolytics. 2018 Aug 28;11:20-38
pubmed: 30306125
Genes Dev. 2007 Jan 1;21(1):98-111
pubmed: 17210792
Nat Rev Immunol. 2011 May;11(5):318-29
pubmed: 21508982
Nat Rev Mol Cell Biol. 2019 Mar;20(3):175-193
pubmed: 30655609
Int J Mol Sci. 2020 Dec 31;22(1):
pubmed: 33396284
FEBS J. 2020 Sep;287(17):3677-3680
pubmed: 32738184
Biomedicines. 2020 Jun 04;8(6):
pubmed: 32512726
Neurochem Int. 2017 Sep;108:100-108
pubmed: 28279751
Mol Cancer. 2019 Aug 23;18(1):128
pubmed: 31443694
Genes Cells. 1998 Nov;3(11):697-707
pubmed: 9990505
Sci Rep. 2016 Jul 26;6:25956
pubmed: 27456282
Mol Cancer. 2021 Feb 25;20(1):41
pubmed: 33632261
Biomed Pharmacother. 2017 Sep;93:1-7
pubmed: 28618251
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Nat Rev Clin Oncol. 2017 Nov;14(11):695-707
pubmed: 28675164
Neurochem Int. 2015 Nov;90:261-70
pubmed: 26455407
Eur J Endocrinol. 2012 Jul;167(1):1-5
pubmed: 22495490
Mol Cancer Ther. 2016 Apr;15(4):661-9
pubmed: 26846818
J Neurol. 2018 Apr;265(4):741-756
pubmed: 29209782
Neurosurg Focus. 2020 Dec;49(6):E10
pubmed: 33260137
Biomedicines. 2019 Nov 11;7(4):
pubmed: 31717973